ArticleMolecular neurobiology2015
Agmatine induces Nrf2 and protects against corticosterone effects in hippocampal neuronal cell line.
Article in Molecular neurobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- From Formulation to Function: γ‑Oryzanol Solid Dispersion Development and Its Neuroprotective Effects on the Depression Model.ACS omega · 2025Article
- Agmatine Abrogates Tacrolimus-Induced Testicular Injury in Rats.Pharmaceutics · 2025Article
- Mitigating effects of agmatine on myocardial infarction in rats subjected to isoproterenol.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Agmatine Enhances Dorsal Raphe Serotonergic Neuronal Activity via Dual Regulation of 5-HTInternational journal of molecular sciences · 2025Article
- Altered Arginine/Agmatine Pathway and Polyamines in Adolescents Diagnosed with Major Depressive Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Article
- Cytoprotective effects of Hangekobokuto against corticosterone-induced cell death in HT22 cells.Journal of natural medicines · 2024Article
- Agmatine-IRF2BP2 interaction induces M2 phenotype of microglia by increasing IRF2-KLF4 signaling.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Antioxidant and Anti-Inflammatory Effects of Carotenoids in Mood Disorders: An Overview.Antioxidants (Basel, Switzerland) · 2023Review
- Protective Effect of Agmatine Against Cisplatin- Induced Cellular Apoptosis in an Auditory Cell Line.The journal of international advanced otology · 2022Article
- Agmatine Mitigates Inflammation-Related Oxidative Stress in BV-2 Cells by Inducing a Pre-Adaptive Response.International journal of molecular sciences · 2022Article
- Quercetin Exhibits α7nAChR/Nrf2/HO-1-Mediated Neuroprotection Against STZ-Induced Mitochondrial Toxicity and Cognitive Impairments in Experimental Rodents.Neurotoxicity research · 2021Article
- Agmatine as a novel candidate for rapid-onset antidepressant response.World journal of psychiatry · 2021Review
- Maintenance of the Neuroprotective Function of the Amino Group Blocked Fluorescence-Agmatine.Neurochemical research · 2021Article
- Protective Effects of Agmatine Against Corticosterone-Induced Impairment on Hippocampal mTOR Signaling and Cell Death.Neurotoxicity research · 2020Article
- Rubrofusarin Attenuates Chronic Restraint Stress-Induced Depressive Symptoms.International journal of molecular sciences · 2020Article
- Xanomeline Protects Cortical Cells From Oxygen-Glucose Deprivation via Inhibiting Oxidative Stress and Apoptosis.Frontiers in physiology · 2020Article
- Short- and Long-Term Repeated Forced Swim Stress Induce Depressive-Like Phenotype in Mice: Effectiveness of 3-[(4-Chlorophenyl)Selanyl]-1-Methyl-1H-Indole.Frontiers in behavioral neuroscience · 2020Article
- Naturally Derived Polyphenols Protect Against Corticosterone-Induced Changes in Primary Cortical Neurons.The international journal of neuropsychopharmacology · 2019Article
- Protective Effects of Ursolic Acid Against Cytotoxicity Induced by Corticosterone: Role of Protein Kinases.Neurochemical research · 2019Article
- Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors.Neurochemical research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperactivation of the hypothalamic-pituitary-adrenal axis is a common finding in major depression; this may lead to increased levels of cortisol, which are known to cause oxidative stress imbalance and apoptotic neuronal cell death, particularly in the hippocampus, a key region implicated in mood regulation. Agmatine, an endogenous metabolite of L-arginine, has been proposed for the treatment of major depression. Corticosterone induced apoptotic cell death and increased ROS production in cultured hippocampal neuronal cells, effects that were abolished in a concentration- and time-dependent manner by agmatine. Interestingly, the combination of sub-effective concentrations of agmatine with fluoxetine or imipramine afforded synergic protection. The neuroprotective effect of agmatine was abolished by yohimbine (α2-adrenoceptor antagonist), ketanserin (5-HT2A receptor antagonist), LY294002 (PI3K inhibitor), PD98059 (MEK1/2 inhibitor), SnPP (HO-1 inhibitor), and cycloheximide (protein synthesis inhibitor). Agmatine increased Akt and ERK phosphorylation and induced the transcription factor Nrf2 and the proteins HO-1 and GCLc; induction of these proteins was prevented by yohimbine, ketanserin, LY294002, and PD98059. In conclusion, agmatine affords neuroprotection against corticosterone effects by a mechanism that implicates Nrf2 induction via α2-adrenergic and 5-HT2A receptors, Akt and ERK pathways, and HO-1 and GCLc expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.